2026-03-15 2026, Volume 1 Issue 1

  • Select all
  • EDITORIAL
    Faming Zhang, Sunny H. Wong, Yang-Yu Liu
  • GUIDELINE
    Faming Zhang, Zheshun Pi, Sunny Hei Wong, Vineet Ahuja, Serena Porcari, Dai Ishikawa, Hailong Cao, Linlin Chen, Ning Chen, Xiong Chen, Bota Cui, Xiao Ding, Xingxiang He, Jia Hu, Jiang Jin, Ji Li, Weiwei Liao, Jingmei Liu, Ling Liu, Yanyan Liu, Yaping Liu, Yu Liu, Chen Lu, Gaochen Lu, Muhan Lv, Xiangjun Meng, Yongzhan Nie, Qian Ren, Lixuan Sang, Xin Sun, Yang Sun, Hongliang Tian, Baohong Wang, Honggang Wang, Liangjing Wang, Xin Wang, Weihong Wang, Zheyu Wang, Yanling Wei, Quan Wen, Lihao Wu, Xia Wu, Lijing Xiong, Guoliang Ye, Bo Yi, You Yu, Yue Zeng, Huihong Zhai, Ting Zhang, Zulun Zhang, Li Zhou, Li Zhu, Kaichun Wu

    As an emerging branch of clinical medicine, microbiota medicine has attracted worldwide attention from clinicians, medical educators, patient communities, and industry. However, this developing field still lacks consensus on its fundamental principles as well as guidelines for clinical and educational practice. An expert panel was convened by the journal Microbiota Medicine Research at the 2025 CHINAGUT Conference to develop the principles and practice guidelines of microbiota medicine using the Delphi method. This document provides a new framework for clinicians, educational institutions, and healthcare administrators. The expert panel developed 15 key statements, encompassing definitions of microbiota medicine and dysbiosis‐related diseases, graded value evaluation of microbiome testing technologies, pathways for multidisciplinary discussions on complex dysbiosis‐related diseases, and educational frameworks for physicians in microbiota medicine. The panel further recommends incorporating microbiota medicine into undergraduate and postgraduate medical education and emphasizes the application of artificial intelligence in supporting microbiota medicine. This guideline defines core competencies required for physicians specializing in this discipline. Collectively, this guideline aims to define the significant role of microbiota medicine in clinical practice and medical education, thereby advancing its sustainable development.

  • REVIEW
    Junyi Chen, Chenfeng Bu, Xia Li, Lei Wu, Xingxiang He

    Fecal microbiota transplantation (FMT), a microbiome‐based therapy, shows potential in treating male sexual dysfunction. Research into the influence of FMT on male sexual function has recently garnered increasing attention. This review aims to explore the impact of FMT on male sexual function and the underlying mechanisms, and to analyze the current research landscape, focusing on key findings and the challenges faced in this evolving field. By critically reviewing and synthesizing the available literature and research outcomes, we intend to provide foundational insights into FMT applications for male sexual health and to outline potential future research trajectories that could further elucidate its benefits and mechanisms.

  • ORIGINAL ARTICLE
    You Yu, Xinlu Jin, Zhaoyang Zhao, Weihong Wang, Fan Xu, Chengran Wang, Sibusiso Luthuli, Xiaoshuang Xu, Quan Wen, Bota Cui, Honggang Wang, Faming Zhang

    Background

    Surgical intervention becomes necessary when conservative treatments fail in patients with Crohn's disease (CD) complicated by intestinal obstruction. Given the limited therapeutic alternatives, this study aimed to evaluate the efficacy of washed microbiota transplantation (WMT) compared with conventional basic treatment in managing intestinal inflammatory obstruction in CD.

    Methods

    In this multicenter, nonrandomized, and concurrent controlled trial, patients with active CD and radiologically confirmed intestinal inflammatory obstruction were enrolled. The WMT group underwent WMT following basic treatment during hospitalization, whereas the non‐WMT group underwent basic treatment alone. Propensity score matching (1:2) was used to balance baseline characteristics. The primary outcome was the obstruction improvement rate at 28 days, with follow‐up continuing until surgery or 3 months post‐discharge.

    Results

    Between March 2018 and March 2024, 48 patients were analyzed after matching, with 16 in the WMT group and 32 in the non‐WMT group. The 28‐day obstruction improvement rate was significantly higher in the WMT group (93.8% vs. 65.6%, p = 0.021). For secondary outcomes, the WMT group showed more favorable trends in 14‐day improvement, as well as in clinical remission and surgery rates assessed at 1 and 3 months after discharge, respectively. In contrast, the obstruction remission rate at 1 month post‐discharge was slightly higher in the non‐WMT group. However, none of these differences reached statistical significance. No severe adverse events occurred in the WMT group.

    Conclusion

    WMT using ileocolic transendoscopic enteral tubing (TET) offers a safe and effective option bridging surgical intervention and conservative treatments in the management of CD with complicated intestinal inflammatory obstruction.

    Trail Registration

    ClinicalTrials.gov NCT01793831, February 2013